Clinical trials
Acute Lymphoblastic Leukemia in Remission clinical trials
Below are recruiting acute lymphoblastic leukemia in remission clinical trials, each written for real people, not researchers. We’re tracking 136 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03314974RecruitingPhase 2
Stem cell transplant study for blood cancers
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT03226704Enrolling by invitation
Leukapheresis to prepare CAR cell therapy
This trial collects white blood cells through a procedure called leukapheresis to help make CAR or other adoptive cell therapies. It’s for people with certain cancers who are not in remission (or are at high risk of relapse) and can meet health and lab requirements.
Bethesda, MarylandAges 3–65 - NCT03081910RecruitingPhase 1
CAR T cells made from your own cells to treat CD5 tumors
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
Houston, TexasAges Up to 75 years - NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT03150693RecruitingPhase 3
New treatment for young adults with CD22-positive ALL
This Phase 3 trial tests adding inotuzumab ozogamicin to standard chemotherapy for newly diagnosed CD22-positive B-cell acute lymphoblastic leukemia (ALL). It may help more patients achieve remission and reduce the risk of the leukemia coming back, while also checking safety and tolerability.
Birmingham, AlabamaAges 18–39 - NCT02877303RecruitingPhase 2
Frontline drug treatment for newly diagnosed B-cell leukemia
This trial tests a combination of targeted and chemotherapy medicines as first treatment for newly diagnosed B-cell acute lymphoblastic leukemia (ALL) or related lymphoblastic lymphoma. It aims to improve how well treatment controls the leukemia and how long people can stay in remission.
Houston, TexasAges 14 years+ - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT02646839Enrolling by invitationPhase 2
Testing a gene-matched transplant approach for childhood leukemia
This trial studies a specific type of partially matched (haploidentical) stem cell transplant in children with ALL, AML, or MDS. It looks at whether using certain immune system gene patterns (KIR) and measuring leftover disease after treatment can improve outcomes and cost-effectiveness.
Los Angeles, CaliforniaAges Up to 21 years - NCT01371630RecruitingPhase 1/Phase 2
Inotuzumab plus chemotherapy for certain types of childhood-like leukemia
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
Houston, TexasAges 18 years+ - NCT06904482RecruitingPhase 2
Stem cell transplant with half-matched donor and cord blood
This trial tests a new way to do a stem cell transplant for people with hard-to-treat blood cancers. It combines a half-matched family donor (haploidentical) with a cord blood unit to help the transplant work better.
Cleveland, OhioAges 18 years+ - NCT03104491RecruitingPhase 1/Phase 2
Inotuzumab after transplant for CD22-positive leukemia
This trial studies inotuzumab ozogamicin, a leukemia-targeting medicine, given after an allogeneic stem cell transplant. It’s for people with CD22-positive acute lymphoblastic leukemia (ALL) to help prevent relapse and improve outcomes after transplant.
Westwood, KansasAges 16–75 - NCT06686108RecruitingPhase 2
Medication combo to prevent lymphoma relapse after transplant
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
ShanghaiAges 14–55 - NCT07072494RecruitingPhase 1/Phase 2
CD19 CAR-T cells as consolidation for B-cell ALL
This trial tests a single infusion of CD19 CAR-T cells as a consolidation treatment to keep leukemia in remission for patients who are not eligible for or decline a stem cell transplant. The goal is to see if this therapy can prevent relapse.
Guangzhou, GuangdongAges 14–80 - NCT04227015RecruitingEarly Phase 1
Study of a CD19 CAR T-cell treatment for relapsed leukemia
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
Hangzhou, ZhejiangAges 3–70 - NCT06393985RecruitingPhase 2
Maintenance therapy after stem cell transplant for B-ALL
This trial tests whether three targeted medicines (decitabine, venetoclax, and blinatumomab) can help prevent leukemia from coming back after a stem cell transplant. It is for people with B-cell ALL who have no detectable remaining leukemia cells and are at least 3 months past transplant.
Suzhou, JiangsuAges 18–65 - NCT07575919RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Standard-Risk B-ALL After Chemotherapy
This trial tests a new type of immunotherapy called CAR-T cells to help prevent relapse in adults with B-cell acute lymphoblastic leukemia (a blood cancer) who have responded well to standard chemotherapy. The treatment is designed as a consolidation therapy to strengthen remission after initial chemotherapy.
Beijing, Beijing MunicipalityAges 18–85 - NCT06756022Recruiting
Dolasetron to prevent nausea from chemo in kids with leukemia
This trial tests if a medicine called dolasetron can prevent chemotherapy-related nausea and vomiting in children with acute lymphoblastic leukemia (ALL). It may help kids feel better during their first round of treatment.
Hefei, AnhuiAges 2–17 - NCT06564493RecruitingPhase 2
Radiation conditioning before sibling stem cell transplant for pediatric ALL
This study tests two types of radiation-based conditioning (TBI or TMLI) before a stem cell transplant from a matched sibling donor, in children with ALL that is in remission. The goal is to see which approach works better and is safer.
Zhengzhou, HenanAges 1–17 - NCT06557161RecruitingPhase 2
Stem cell transplant with TBI or TMLI for adult ALL
This trial tests two different conditioning regimens (total body irradiation or total marrow/lymphoid irradiation) before a stem cell transplant from a matched sibling donor for adults with acute lymphoblastic leukemia (ALL) that is in remission. The goal is to see which regimen works better and has fewer side effects.
Zhengzhou, HenanAges 18–65 - NCT06559345RecruitingPhase 2
Stem cell transplant study for children with ALL in remission
This trial tests a stem cell transplant using a half-matched family donor for children with acute lymphoblastic leukemia (ALL) that is in remission. It compares two different types of radiation conditioning to prepare the body for the new cells, with the goal of improving outcomes.
Zhengzhou, HenanAges 1–17 - NCT06564545RecruitingPhase 2
Radiation-based transplant preparation for adult ALL
This trial studies a new way to prepare adults with ALL for a stem cell transplant from a half-matched family donor. It compares two types of radiation-based conditioning to see which works better and has fewer side effects.
Zhengzhou, HenanAges 18–65 - NCT06866873Recruiting
CAR-T cell therapy for kids with ALL or lymphoma
This trial tests a special immune cell treatment (CAR-T cells) for children whose leukemia or lymphoma has come back or not responded to at least two prior treatments. The goal is to see if these cells can find and destroy the cancer.
Hong KongAges 1–17 - NCT07250087RecruitingPhase 1
Asciminib maintenance after transplant or CAR T for Ph+ALL
This trial tests a pill called asciminib given after a stem cell transplant or CAR T therapy to help prevent relapse in adults with Philadelphia chromosome-positive ALL. It is for people whose cancer is currently in remission.
Tampa, FloridaAges 18 years+
Hear when a new Acute Lymphoblastic Leukemia in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute lymphoblastic leukemia in remission?
- Yes. Clin2 currently lists 136 recruiting acute lymphoblastic leukemia in remission studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute lymphoblastic leukemia in remission trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute lymphoblastic leukemia in remission trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Acute Lymphoblastic Leukemia With Failed Remission
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- Acute Lymphoblastic Leukemia
- B-cell Acute Lymphoblastic Leukemia
- Refractory Acute Lymphoblastic Leukemia
- T-cell Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphoblastic Leukemia, Adult
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.